Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

Kidney Cancer Clinical Trial

Official title:

A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00057889
• Other study ID #: 030094
• Secondary ID: 03-C-0094CDR0000
• Status: Completed
• Phase: Phase 2
• First received: April 7, 2003
• Last updated: March 14, 2012
• Start date: February 2003
• Est. completion date: February 2008

Study information

• Verified date: March 2012
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have metastatic renal cell cancer (kidney cancer) that is refractory to treatment with interleukin-2 or unable to be treated with interleukin-2.

Description:

OBJECTIVES:

• Determine the activity of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody in patients with metastatic clear cell renal cancer who are refractory to or ineligible for interleukin-2.

• Determine the impact of this drug on T-cell number and phenotype in these patients.

OUTLINE: This is an open-label study.

Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes once every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with an ongoing partial response may receive additional courses of therapy.

Patients are followed at 4 weeks, every 3 months for 1 year, every 6 months for 2 years, and then annually until disease progression.

PROJECTED ACCRUAL: A total of 21-103 patients will be accrued for this study within 2-4 years.

Other known NCT identifiers

• NCT00053729

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: February 2008
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed stage IV clear cell renal carcinoma

• At least 1 site of measurable disease

• Meeting criteria for 1 of the following:

• Disease progression after prior interleukin-2 (IL-2)

• Ineligible for standard high-dose IV IL-2 due to comorbid medical conditions

• Minimal disease (lesions = 3 cm that do not pose risk to organ function) such that participation in this study is not likely to compromise the patient's opportunity to receive future high-dose IL-2

• Indolent disease (defined as an increase in tumor size of < 50% within the past 6 months) such that participation in this study is not likely to compromise the patient's opportunity to receive future high-dose IL-2

• No true papillary, medullary, chromophobe, collecting duct, or oncocytic renal cancer

PATIENT CHARACTERISTICS:

Age

• 16 and over

Performance status

• ECOG 0-1

Life expectancy

• At least 3 months

Hematopoietic

• WBC = 2,500/mm^3

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 100,000/mm^3

• Hemoglobin = 10 g/dL

• Hematocrit = 30%

Hepatic

• AST = 3 times upper limit of normal (ULN)

• Bilirubin = ULN (< 3.0 mg/dL for patients with Gilbert's syndrome)

• Hepatitis B surface antigen negative

• Hepatitis C antibody negative

Renal

• Creatinine < 2.0 mg/dL

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• HIV negative

• No other malignancy except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or any other cancer from which the patient has been disease free for at least 5 years

• No autoimmune disease (including uveitis and autoimmune inflammatory eye disease)

• No active uncontrolled infection

• No other medical condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

• No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody

• At least 3 weeks since prior immunotherapy for renal cancer

Chemotherapy

• At least 3 weeks since prior chemotherapy for renal cancer

• No concurrent chemotherapy

Endocrine therapy

• At least 3 weeks since prior hormonal therapy for renal cancer

• More than 4 weeks since prior corticosteroids

• No concurrent systemic or topical corticosteroids

Radiotherapy

• At least 3 weeks since prior radiotherapy for renal cancer

Surgery

• Not specified

Other

• Recovered from prior therapy

• At least 3 weeks since other prior therapy for renal cancer

• No concurrent immunosuppressive agents (e.g., cyclosporine and its analog)

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Cancer

Intervention

Biological:
• ipilimumab

Locations

Country	Name	City	State
United States	Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support	Bethesda	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
National Institutes of Health Clinical Center (CC)	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States,